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Abstract
Background: Health-related quality of life (HRQL) is an important patient-reported outcome measure used to describe
the burden of chronic obstructive pulmonary disease (COPD) which is often accompanied by comorbid conditions.
Methods: Data from 2275 participants in the COPD cohort COSYCONET and from 4505 lung-healthy control subjects
from the population-based KORA and SHIP studies were pooled. Main outcomes were the five dimensions of the generic
EQ-5D-3 L questionnaire and two EQ-5D index scores using a tariff based on valuations from the general population and
an experience-based tariff.
The association of COPD in GOLD grades 1–4 and of several comorbid conditions with the EQ-5D index scores was
quantified by multiple linear regression models while adjusting for age, sex, education, body mass index (BMI),
and smoking status.
Results: For all dimensions of the EQ-5D, the proportion of participants reporting problems was higher in the
COPD group than in control subjects. COPD was associated with significant reductions in the EQ-5D index scores
(-0.05 points for COPD grades 1/2, -0.09 for COPD grade 3, -0.18 for COPD grade 4 according to the preference-based
utility tariff, all p< 0.0001). Adjusted mean index scores were 0.89 in control subjects and 0.85, 0.84, 0.81, and 0.72 in COPD
grades 1-4 according to the preference-based utility tariff and 0.76, 0.71, 0.68, 0.64, and 0.58 for control subjects and COPD
grades 1-4 for the experience-based tariff respectively. Comorbidities had additive negative effects on the index scores;
the effect sizes for comorbidities were comparable to or smaller than the effects of COPD grade 3. No statistically
significant interactions between COPD and comorbidities were observed. Score differences between COPD patients
and control subjects were most pronounced in younger age groups.
(Continued on next page)
* Correspondence: margarethe.wacker@helmholtz-muenchen.de
1Institute of Health Economics and Health Care Management, Helmholtz
Zentrum München (GmbH) - German Research Center for Environmental
Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the
German Center for Lung Research (DZL), Ingolstädter Landstr. 1, 85764
Neuherberg, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wacker et al. Respiratory Research  (2016) 17:81 
DOI 10.1186/s12931-016-0401-0
(Continued from previous page)
Conclusions: Compared with control subjects, the considerable reduction of HRQL in patients with COPD was mainly
due to respiratory limitations, but observed comorbidities added linearly to this effect. Younger COPD patients showed
a greater loss of HRQL and may therefore be in specific need of comprehensive disease management.
Trial registration: NCT01245933
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Background
Chronic obstructive pulmonary disease (COPD) is a highly
prevalent disease and the fourth leading cause of death
worldwide [1]. Therefore, COPD represents a major pub-
lic health challenge [2]. Patients with COPD are affected
to a varying extent by symptoms such as chronic cough,
phlegm, dyspnea, and by acute exacerbations or episodes
of acute worsening of the respiratory symptoms. These
characteristics of COPD are associated with limitations in
health-related quality of life (HRQL) [3–7]. Furthermore,
HRQL in patients with COPD is also affected by comorbid
conditions [8, 9] which are common due to advanced age,
common risk factors such as smoking, and the presence
of systemic inflammation [10, 11]. Although several stud-
ies have demonstrated that comorbidities contribute to
low HRQL in patients with COPD [9, 12–14], there is no
evidence whether the effect of comorbid conditions on
HRQL differs between patients with COPD and individ-
uals without COPD.
Quantifying HRQL is important at the level of individual
patients to assess their limitations, the course of disease
over time, and the effects of medical interventions. How-
ever, HRQL assessment is also essential from a scientific
perspective as patient-reported outcomes are important
endpoints in clinical studies [15]. For health economic pur-
poses, the effectiveness of health interventions is increas-
ingly quantified using quality-adjusted life years (QALYs)
that combine quality and quantity of life into one outcome.
Health utilities as a preference-based valuation of health
states and a measure of quality can be derived by some gen-
eric HRQL instruments such as the EQ-5D questionnaire.
These utilities are crucial input parameters for economic
COPD models estimating the cost-effectiveness of interven-
tions. The use of national tariffs is recommended for the
calculation of utilities whenever possible [16].
This study aims to quantify the impact of COPD on
generic HRQL relative to lung-healthy individuals. There-
fore, it compares the EQ-5D-3 L questionnaire between a
large sample of COPD patients in all grades of airflow
limitation and lung-healthy control subjects from two
pooled population-based studies. The association of se-
lected comorbid conditions with HRQL is analyzed in
COPD patients and control subjects, which allows separ-
ation of the effect of COPD on HRQL from the effect of
comorbidities. The underlying hypotheses were that 1)
HRQL in patients with COPD is impaired compared to
control subjects, 2) HRQL deteriorates with increasing
COPD grade and 3) comorbidities add to the effect of
COPD on HRQL. Finally, national reference values on
utilities in different COPD grades are reported that will be
useful for economic evaluations of COPD.
Methods
Study sample
This is a cross-sectional analysis of three pooled data
sources. Data from the baseline visit of the German na-
tional COPD cohort COSYCONET (“COPD and Sys-
temic Consequences - Comorbidities Network”) were
compared with a lung-healthy control group from the
population-based KORA (“Cooperative Health Research
in the Augsburg Region”) platform in Southern Germany
and the SHIP (“Study of Health in Pomerania”) cohorts
in Northern Germany.
The COSYCONET cohort recruited 2741 subjects
aged ≥ 40 years with physician-diagnosed COPD between
September 2010 and December 2013 through outpatient
and inpatient healthcare providers, patient groups, and
media campaigns and examined them in 31 study cen-
ters all over Germany. Exclusion criteria were previous
lung transplantation or lung volume reduction surgery
and lung malignancies. All participants had to be clinic-
ally stable at their examination visit defined as no mod-
erate or severe exacerbations for at least 4 weeks at the
time of enrollment. Details on the cohort have been
published previously [17, 18].
The KORA platform comprises population-based
health surveys with subsequent follow-up studies in the
Augsburg region [19]. Two studies with lung function
data were used: Within the KORA F4L study (2010)
spirometry was performed in 1051 participants aged 44–
65 years. The KORA Age 1 study (2008) recruited par-
ticipants from previous KORA studies aged 65–89 years
and examined lung function by spirometry in a ran-
domly selected sample of 1079 participants [20].
SHIP is a population-based, epidemiological project
consisting of two independent cohorts, SHIP and SHIP-
TREND, selected from the counties of North- and East
of Western Pomerania and the two cities of Greifswald
and Stralsund [21]. Data from 1348 participants in the
SHIP S2 study (2008–2012) and 2137 SHIP TREND
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participants (2008–2012) who were aged 40 years or
older and performed spirometry were used.
Figure 1 provides a study flow chart. Pooled data from
the KORA Age 1, KORA F4L, SHIP S2 and SHIP-TREND
studies covered the general population in an age range of
40–90 years, which is comparable to the COPD cohort.
Definition of COPD patients and lung-healthy control
subjects
In the COSYCONET COPD cohort, standardized spirom-
etry was performed after bronchodilation [17]. In KORA
and SHIP, spirometry was performed without bron-
chodilation. In all studies, COPD was defined as FEV1/
FVC < 0.7 according to the GOLD criteria [2]. Participants
with COPD according to this definition were excluded
from the lung-healthy control groups taken from KORA
and SHIP, as well as 92 KORA participants and 117 SHIP
participants with a self-reported history of asthma.
COPD patients from the COSYCONET cohort were
classified as grade 1 with FEV1 % pred. ≥ 80, grade 2 with
50 ≤ FEV1 % pred. < 80, grade 3 with 30 ≤ FEV1 % pred. <
50, and grade 4 with FEV1 % pred. < 30. Predicted values
were taken from the Global Lung Initiative (GLI) [22]. A
total of 430 participants from the cohort reporting
physician-diagnosed COPD but with FEV1/FVC ≥ 0.7 were
excluded from this analysis, as well as 20 participants with
incomplete or missing lung function data.
HRQL assessment
The main outcome of this analysis was the EQ-5D-3 L
questionnaire as a generic HRQL instrument that assesses
current health status without specifying a recall period. Its
descriptive section covers five dimensions of health: mobil-
ity, self-care, usual activities, pain/discomfort, and anxiety/
depression, with three levels per item (1: no problems, 2:
some problems, and 3: extreme problems). The second part
of the questionnaire, the valuation section, comprises a
Visual Analog Scale (VAS) for valuing health status on a
rating scale from 0 (worst imaginable health state) to 100
(best imaginable health state). The VAS was not available in
SHIP and KORA.
There are several tariffs for the scoring or valuation of
243 theoretically possible health states as described by the
five dimensions of the EQ-5D-3 L questionnaire on a
single metric (EQ-5D index) that ranges between 0 and 1
with higher values indicating better health. Country-
specific tariffs are preferred to reflect the valuation of
health concerns by the specific population. A key aspect
of tariffs is whether the valuations come from a represen-
tative sample of individuals that values hypothetical health
states or from individuals who value their own, current
Fig. 1 Study flow chart
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health state [23]. Traditional tariffs are based on the valu-
ation of hypothetical or given health states (GHS) by the
general population. They reflect preferences that individ-
uals or society may have for any particular set of health
outcomes in a situation of choice and can be interpreted
as preference-based utilities. As a broad measure of bene-
fits, utilities are essential for the quality-adjustment of life
years and can be used in guiding resource allocation deci-
sions. Alternative methods use the valuation of people
who experience an actual health state, referred to as expe-
rienced health states (EHS), as these individuals have best
insight regarding their health state.
In this analysis, we used the available German time-
trade-off tariff of Greiner et al. [24], which is based on the
valuation of GHS by a general population sample. The EQ-
5D-3 L index resulting from this approach is subsequently
referred to as the EQ-5D utility score. As the VAS was not
available in all studies, we also used a recently developed
German population EQ-5D index from Leidl et al. that is
based on EHS [25]. This index uses the VAS for the valu-
ation of health states of the EQ-5D-3 L and is therefore
based on the valuation of health states by those who experi-
ence this health state instead of the general public. The
EQ-5D-3 L index resulting from this additional approach is
subsequently referred to as the EQ-5D valuation score.
Over all studies, 69 participants with missing or incom-
plete EQ-5D data were excluded.
Covariates and comorbidities
In all studies, participants’ characteristics and data on
comorbid conditions were assessed in standardized
interviews and questionnaires. Participants’ age and sex
were considered as well as their level of school educa-
tion (basic education ≤9 years, secondary education 10-
11 years, higher education > 11 years), body mass index
(BMI, kg/m2, determined from measured height and
weight), and smoking status (smokers were defined as
individuals who reported regular or occasional active
cigarette smoking within the 4 weeks prior to the inter-
view; former smokers were defined as individuals who
reported regular or occasional active cigarette smoking
in the past; never smokers were defined as individuals
who reported no active cigarette smoking over lifetime).
For four COSYCONET participants with missing inf-
ormation on smoking status, former smoking as the
most frequent category was assumed. The presence of
comorbidities was assessed by asking participants the
question: “Has a physician ever diagnosed you with one
of the following diseases?”. Information on diabetes,
cancer, stroke, myocardial infarction, and arthritis as
frequent comorbid conditions was assessed in all studies
in a comparable way and considered as comorbidities.
Ninety-five observations with missing information re-
garding covariates were excluded from this analysis.
Statistical analysis
Characteristics of COPD patients in different grades and
of control subjects were compared using analysis of vari-
ance (ANOVA) for continuous variables or for unadjusted
means of the EQ-5D scores and Chi2-tests for categorical
variables.
Multiple linear regression models (ordinary least squares,
OLS) were conducted to assess the association between
COPD in grades 1–4 and the EQ-5D index scores while
adjusting for possible confounders.
To quantify the impact of comorbidities on HRQL, all
analyses were performed with and without regression
adjustment for comorbidities. This approach allows the
division of the estimated effect of COPD into a part
related to COPD itself and a part related to associated
comorbidity. In the first step, the basic models included
age group, sex, and level of school education as covariates.
Extended models considered smoking status and BMI as
possible risk factors and the selected comorbidities as add-
itional covariables.
Interactions between COPD and comorbidities were ana-
lyzed by variable selection methods (PROC GLMSELECT
with backward selection method) in order to examine non-
additive effects of comorbidities on HRQL. In addition, re-
gression models were performed separately for COPD cases
and control subjects to investigate possible differences in
the effects of comorbidities in each group.
Although numerous studies have based the analysis of
EQ-5D index scores on OLS [6, 26, 27], we additionally
performed a sensitivity analysis with generalized linear
regression models assuming a beta distribution with
logit-link [28] in order to account for the skewed and
censored distribution of the EQ-5D index scores.
Statistical analyses were performed using SAS soft-
ware (SAS Institute Inc., Cary, NC, USA, version 9.3),
and p-values of 0.05 or less were considered to be
statistically significant.
Results
The characteristics of the 2275 participants in the COPD
cohort and of 4505 lung-healthy control subjects are
shown in Table 1. The COPD cohort had a higher mean
age than the pooled control group (65.1 vs. 59.9 years,
p < 0.0001), a higher proportion of males (61.1 vs.
49.3 %, p < 0.0001) and of participants with basic educa-
tion (55.3 vs. 33.3 %, p < 0.0001). The proportion of never
smokers was lower in the COPD cohort than in control
subjects (6.5 % vs. 42.8 %, p < 0.0001) as well as the mean
BMI (26.7 vs. 28.4 kg/m2, p < 0.0001). Regarding comor-
bidities, stroke, cancer, and myocardial infarction were
reported significantly more often in the COPD cohort
than in the control group.
For the EQ-5D dimensions mobility, usual activities,
and anxiety/depression, the proportion of participants
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p-value (total cohort vs.
pooled control subjects)
n 1,506 2,999 4,505 204 954 869 248 2,275
age (years) 63.4 (11.8) 58.1 (10.8) 59.9 (11.4) 66.1 (8.7) 65.7 (8.5) 65.0 (8.2) 62.1 (8.0) 65.1 (8.4) <0.0001a
% age < 55 years 28.0 (421) 39.7 (1,190) 35.8 (1,611) 9.8 (20) 10.2 (97) 11.1 (96) 18.2 (45) 11.3 (258) <0.0001b
% age 55-64 years 28.0 (421) 28.8 (863) 28.5 (1,284) 27.5 (56) 31.9 (304) 34.4 (299) 43.2 (107) 33.7 (766)
% age 65-74 years 21.4 (322) 24.5 (734) 23.4 (1,056) 48.0 (98) 44.6 (425) 44.0 (382) 31.9 (79) 43.3 (984)
% age > 74 years 22.7 (342) 7.1 (212) 12.3 (554) 14.7 (30) 13.4 (128) 10.6 (92) 6.9 (17) 11.7 (267)
% males 48.1 (724) 49.9 (1,496) 49.3 60.3 (123) 60.6 (578) 61.1 (531) 64.1 (159) 61.1 <0.0001b
FEV1 (liter) 3.06 (0.9) 3.16 (0.8) 3.13 (0.8) 2.62 (0.6) 1.85 (0.5) 1.20 (0.3) 0.75 (0.2) 1.55 (0.6) <0.0001
a
FVC (liter) 3.92 (1.1) 3.96 (1.0) 3.95 (1.1) 4.11 (0.9) 3.31 (0.9) 2.67 (0.8) 2.05 (0.6) 3.00 (1.0) <0.0001a
% basic education
(≤9 school years)
56.2 (847) 21.8 (854) 33.3 (1,501) 48.0 (98) 52.1 (497) 60.0 (521) 57.7 (143) 55.3 (1,259) <0.0001b
% secondary education
(10–11 school years)
22.7 (342) 52.8 (1,584) 42.8 (1,926) 25.5 (52) 28.6 (273) 25.2 (219) 29.4 (73) 27.1 (617)
% higher education
(>11 school years)
21.1 (317) 25.4 (761) 23.9 (1,078) 26.5 (54) 19.3 (184) 14.8 (129) 12.9 (32) 17.5 (399)
% smoker 11.3 (170) 16.1 (484) 14.5 (654) 29.9 (61) 28.9 (276) 21.8 (189) 14.5 (36) 24.7 (562) <0.0001b
% former smoker 39.2 (590) 44.4 (1,332) 42.7 (1,922) 62.8 (128) 63.7 (608) 72.6 (631) 80.2 (199) 68.8 (1,566)
% never smoker 49.5 (746) 39.5 (1,183) 42.8 (1,929) 7.4 (15) 7.3 (70) 5.6 (49) 5.2 (13) 6.5 (147)
BMI (kg/m2) 28.2 (4.7) 28.6 (4.7) 28.4 (4.7) 26.6 (4.7) 27.5 (5.1) 26.4 (5.4) 24.4 (5.0) 26.7 (5.2) <0.0001a
% normal weight
(18.5≤ BMI < 25)
24.4 (368) 22.7 (681) 23.3 (1,049) 36.8 (75) 32.5 (310) 38.4 (334) 50.0 (124) 37.1 (843) <0.0001b
% overweight
(25≤ BMI < 30)
45.8 (690) 43.8 (1,313) 44.5 (2,003) 41.7 (85) 39.0 (372) 36.1 (314) 28.6 (71) 37.0 (842)
% obese (BMI≥ 30) 29.6 (445) 33.4 (1,003) 32.1 (1,448) 20.1 (41) 27.0 (258) 20.9 (182) 11.7 (29) 22.4 (510)
% underweight
(BMI < 18.5)
0.2 (3) 0.1 (2) 0.1 (5) 1.5 (3) 1.5 (14) 4.5 (39) 9.7 (24) 3.5 (80)
% diabetes 10.4 (156) 13.3 (399) 12.3 (555) 10.3 (21) 13.3 (127) 12.8 (111) 11.3 (28) 12.6 (287) 0.73b
% stroke 4.1 (61) 2.5 (75) 3.0 (136) 3.9 (8) 4.3 (41) 4.8 (42) 2.4 (6) 4.3 (97) 0.008b
% myocardial infarction 5.1 (76) 3.5 (106) 4.0 (182) 6.4 (13) 8.8 (84) 9.6 (83) 5.2 (13) 8.5 (193) <0.0001b
% cancer 9.5 (143) 8.1 (242) 8.6 (385) 11.8 (24) 12.2 (116) 10.1 (88) 7.3 (18) 10.8 (246) 0.002b
% arthritis 12.4 (186) 5.6 (168) 7.9 (354) 10.3 (21) 8.1 (77) 8.6 (75) 4.8 (12) 8.1 (185) 0.69b
EQ-5D utility score 0.90 (0.14) 0.90 (0.14) 0.90 (0.14) 0.85 (0.18) 0.84 (0.19) 0.81 (0.21) 0.74 (0.24) 0.82 (0.21) <0.0001a
EQ-5D valuation score 0.76 (0.14) 0.77 (0.13) 0.77 (0.13) 0.71 (0.14) 0.68 (0.16) 0.64 (0.17) 0.58 (0.17) 0.66 (0.17) <0.0001a
Data are mean (standard deviation) or percentage











reporting some or extreme problems was higher in the
COPD groups than in control subjects and increased with
higher COPD grade, as illustrated in Fig. 2. Especially for
mobility and usual activities, a large proportion of COPD
patients reported some or extreme problems, with up to
79 % of participants in COPD grade 4 for usual activities.
Regarding self-care, the proportion of participants report-
ing problems was comparable in COPD grade 1 and the
control group, but steadily increased from grade 2 to
grade 4 in the COPD group. As to pain and discomfort, a
slightly higher proportion of COPD patients reported
problems compared with control subjects, but within the
COPD group, proportions were comparable with 70.6 %
in grade 1 and 64 % in grade 3.
Unadjusted mean EQ-5D utility and valuation scores for
COPD grades 1–4 were lower than in the control group
and decreased with increasing disease severity (Table 1).
Table 2 shows the results of the regression analyses.
After adjusting for differences in age, sex, and education
between groups, all COPD grades were associated with
statistically significant reductions in both index scores.
This reduction increased with higher disease grade. The
effect estimates of COPD grades 1 and 2 were of a similar
magnitude when considering the utility score and differed
slightly when considering the valuation score. When con-
trolling for smoking status, weight, and comorbidities in
extended regression models, the negative effects of COPD
grades 1–4 remained stable. All comorbid conditions had
additional negative effects on the index scores; these ef-
fects were additive as all interaction terms between COPD
grade and comorbid conditions were not statistically sig-
nificant (results not shown). The effect sizes for comor-
bidities were comparable to or smaller than the effects of
COPD grade 3, whereby a history of arthritis or stroke
had the largest effects. The effect estimate of obesity was
similar to the estimate of COPD grades 1 or 2.
Table 3 shows the effect estimates of comorbid condi-
tions, stratified for the COPD cohort and the control
group. Most of the estimates were comparable in cases
and control subjects. Figure 3 shows the adjusted mean
index scores for all groups resulting from the basic
regression model. Figure 4 illustrates adjusted mean
index scores by age group. For both index scores, the
gap between COPD patients and control subjects was
more pronounced in younger than in older age groups.
The adjusted mean index scores based on a model
assuming a beta-distribution with logit-link differed only
marginally from those of the OLS models: a difference
of -0.01 to +0.03 was observed for the means of the
groups according to utility score and -0.01 to +0.01
according to the valuation score.
Discussion
Based on a large pooled data set, this study corroborates
the significant reduction of generic HRQL in patients
with COPD compared with lung-healthy control sub-
jects. HRQL limitations increased with higher COPD
disease grade. The coexistence of COPD with other dis-
eases contributes to the overall burden by increasing
HRQL limitations. Therefore, comorbid conditions are
important to assess in the context of COPD manage-
ment. The novel finding of this study was that the
HRQL reductions were found to be primarily due to the
lung disorder, whereas the effects of comorbidities were
weaker and additive. Comorbid arthritis, stroke, and
obesity had the largest additional effects on the HRQL
index scores. However, significant interactions between
COPD grades and comorbidities were not found. Not-
ably, the HRQL gap between COPD patients and control
subjects was larger in younger than in older age groups,
which could be explained by a higher impact of dyspnea
on HRQL [29]. As an individualized, patient-centered
approach is postulated as the ideal care of COPD
patients [30], younger patients with COPD may be an
important target group for specific disease management.
Fig. 2 EQ-5D dimensions: % of participants reporting problems (unadjusted)
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Table 2 Results of multiple linear regression models
EQ-5D utility score EQ-5D valuation score
Covariate Basic model Extended model Basic model Extended model
Intercept 0.91 [0.90 to 0.92] 0.96 [0.94 to 0.97] 0.78 [0.77 to 0.79] 0.82 [0.81 to 0.83]
COPD no COPD ref. ref. ref. ref.
grade 1 −0.04 [-0.06 to -0.02] −0.05 [-0.07 to -0.02] −0.05 [-0.07 to -0.03] −0.06 [-0.07 to -0.04]
grade 2 −0.05 [-0.06 to -0.04] −0.05 [-0.06 to -0.04] −0.08 [-0.09 to -0.07] −0.08 [-0.09 to -0.07]
grade 3 −0.08 [-0.09 to -0.07] −0.09 [-0.10 to -0.08] −0.12 [-0.13 to -0.11] −0.13 [-0.14 to -0.12]
grade 4 −0.16 [-0.18 to -0.14] −0.18 [-0.20 to -0.15] −0.18 [-0.20 to -0.16] −0.20 [-0.21 to -0.18]
Age (years) < 55 ref. ref. ref. ref.
55-64 −0.02 [-0.04 to -0.01] −0.01 [-0.02 to 0.00] −0.03 [-0.04 to -0.02] −0.02 [-0.02 to -0.01]
65-74 −0.02 [-0.03 to -0.01] −0.01 [-0.02 to 0.00] −0.01 [-0.02 to -0.00] 0.00 [-0.01 to 0.01]
> 74 −0.06 [-0.07 to -0.04] −0.04 [-0.05 to -0.02] −0.06 [-0.07 to -0.04] −0.04 [-0.05 to -0.02]
Sex male ref. ref. ref. ref.
female −0.01 [-0.02 to -0.01] −0.02 [-0.03 to -0.01] −0.02 [-0.03 to -0.02] −0.03 [-0.04 to -0.02]
Education basic (≤ 9 school years) ref. ref. ref. ref.
secondary (10-11 school years) 0.01 [0.01 to 0.02] 0.01 [-0.00 to 0.02] 0.02 [0.01 to 0.02] 0.01 [0.00 to 0.02]
higher (>11 school years) 0.04 [0.03 to 0.05] 0.03 [0.02 to 0.04] 0.04 [0.03 to 0.05] 0.03 [0.02 to 0.04]
Smoking status never smoker ref. ref.
smoker −0.02 [-0.03 to -0.00] −0.01 [-0.02 to -0.00]
former smoker −0.01 [-0.02 to -0.00] −0.01 [-0.01 to 0.00]
Weight normal weight (18.5≤ BMI < 25) ref. ref.
underweight (BMI < 18.5) 0.00 [-0.03 to 0.04] 0.01 [-0.02 to 0.04]
overweight (25≤ BMI < 30) −0.02 [-0.03 to -0.01] −0.02 [-0.02 to -0.01]
obese (BMI≥ 30) −0.05 [-0.06 to -0.04] −0.05 [-0.06 to -0.04]
Comorbidities diabetes −0.03 [-0.04 to -0.02] −0.02 [-0.04 to -0.01]
stroke −0.05 [-0.07 to -0.03] −0.05 [-0.07 to -0.03]
myocardial infarction −0.04 [-0.05 to -0.02] −0.04 [-0.05 to -0.02]
cancer −0.02 [-0.04 to -0.01] −0.02 [-0.03 to -0.01]
arthritis −0.08 [-0.10 to -0.07] −0.08 [-0.09 to -0.07]
Estimates with p < 0.05 are printed in bold
Table 3 Association of comorbid conditions with the EQ-5D index scores stratified for COPD cases and control subjects
EQ-5D utility score EQ-5D valuation score
Covariate COPD cases Control subjects COPD cases Control subjects
Diabetes −0.03 [-0.05 to -0.00] −0.03 [-0.05 to -0.02] −0.01 [-0.03 to 0.01] −0.03 [-0.05 to -0.02]
Stroke −0.04 [-0.08 to 0.00] −0.05 [-0.08 to -0.03] −0.03 [-0.06 to 0.00] −0.06 [-0.08 to -0.04]
Myocardial infarction −0.05 [-0.08 to -0.02] −0.02 [-0.04 to -0.00] −0.05 [-0.07 to -0.02] −0.03 [-0.05 to -0.01]
Cancer −0.03 [-0.05 to -0.00] −0.02 [-0.03 to -0.00] −0.02 [-0.04 to 0.00] −0.03 [-0.04 to -0.01]
Arthritis −0.09 [-0.12 to -0.06] −0.08 [-0.09 to -0.06] −0.07 [-0.10 to -0.05] −0.08 [-0.09 to -0.06]
Obesity (BMI≥ 30) −0.06 [-0.08 to -0.04] −0.04 [-0.05 to -0.03] −0.04 [-0.06 to -0.02] −0.04 [-0.05 to -0.05]
Estimates with p < 0.05 are printed in bold
Models adjusted for age, sex, education, BMI class, and smoking status
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The EQ-5D questionnaire is the most frequently used
instrument for the calculation of health utilities and recom-
mended by several reimbursement and academic author-
ities worldwide [31]. The validity, reliability, responsiveness,
and discriminative properties of the EQ-5D in populations
with COPD have been examined in several studies [5, 12,
32–34]. For the EQ-5D index scores used in this study, a
minimal clinically important difference (MCID) has not yet
been established. Based on studies using other scoring
algorithms and in diseases other than COPD, it may range
between 0.04 and 0.07 [35, 36]. Therefore, the effects for
COPD grades observed in this study can be seen as clinic-
ally relevant.
This evidence corroborates previous studies that have
already shown that increasing disease severity in COPD is
associated with a reduction in EQ-5D utility and other
generic or disease-specific HRQL scores [37–40]. How-
ever, it also expands previous evidence as there is a lack of
studies considering the entire spectrum of disease grades
and a comparison with control subjects [6, 12, 39]. The
variation in published mean EQ-5D utility scores per
COPD grade is considerable. Besides diverging underlying
Fig. 3 Adjusted mean EQ-5D index scores. Models adjusted for age, sex, and education
Fig. 4 Adjusted EQ-5D index score stratified by age group. Models adjusted for age, sex, and education
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populations and definitions of COPD, the comparability of
utilities with previous studies is hampered by differences
in the scoring algorithms for the EQ-5D index. Differences
between national EQ-5D tariffs have been shown to be
substantial because of different methodological approaches,
but also, to a minor degree, due to cultural differences in
valuation. As these differences may influence the results of
cost-utility analyses [16], national data on utilities are re-
quired for economic evaluations of COPD in Germany.
Einarson et al. reviewed 44 original articles that
reported utilities related to COPD [41]. Irrespective of
disease classification and utility instrument, methods or
tariffs used, mean utilities were 0.83, 0.77, 0.71, and 0.61
for GOLD grades 1–4 respectively. A review by Pickard
et al. reported pooled mean utility scores based on a UK
scoring algorithm of 0.74, 0.74, 0.69, and 0.61 for GOLD
grades 1–4 [40]. Especially for early COPD grades the
pooled mean utilities reported by Pickard et al. were
lower than those found in this analysis and those
reported by Einarson et al. Similar to Pickard et al., our
study found comparable mean utilities for GOLD grades
1 and 2. This finding might be explained by possible
ceiling effects of the EQ-5D questionnaire that limit the
ability of this instrument to discriminate well between
early COPD grades and have been described previously
[6, 12, 34]. Nevertheless, the availability of control sub-
jects enabled us to show a reduction in the EQ-5D index
scores even in early disease grades.
There are only a few studies that have considered the ef-
fect of comorbidities on utilities in COPD patients. Most
of them used the number of comorbid conditions or a
weighted comorbidity index and found that a higher num-
ber of comorbidities is associated with a reduced utility
[12, 14, 34]. By pooling data from patients with COPD
and lung-healthy control subjects, we were able to separ-
ate the effect of COPD on HRQL from the effect of
comorbidities. Our results show that the effects of com-
orbid conditions on the EQ-5D index scores were com-
parable between patients with COPD and lung-healthy
control subjects and the size of comorbid effects was
equal to or even smaller than the impact of COPD grade
3. Arthritis and stroke showed the highest effects and are
therefore in need of special consideration. In line with our
results, a previous study also did not find interactions or
effect-modifications between COPD disease severity and
comorbidity [12]. However, a comparison with control
subjects was not considered.
The main strength of this study lies in the large sam-
ple size covering all COPD grades and the availability of
control subjects from two population-based cohort stud-
ies. Individual data with standardized variable definitions
could be pooled for this analysis.
Besides the established German EQ-5D utility tariff [24],
an experience-based tariff for the valuation of health states
into a single index score was additionally considered.
Although national utility scores are needed for the calcula-
tion of QALYs and for cost-utility analyses in COPD,
experience-based scores may be important for decision
makers who want to base their decisions on experienced
health states rather than on the valuation of these health
states by the general population [25, 42]. Whereas the util-
ity tariff includes preferences on hypothetical health states,
the valuation by the experience-based tariff refers to the
health state of respondents, and valuation is done by VAS
[25]. Both differences may contribute to the finding that
valuations of the experience-based index are lower than
those of the utility-tariff. As shown by another study of
the COSYCONET cohort, preference-based utilities and
patients’ VAS valuations may also differ: Between grade 1
and 4, the utility-tariff indicated a difference of 0.13 while
for patients’ valuations, this was 0.22 [34], thus making
the choice of valuation used in this study important to the
results obtained.
This study is subject to methodologic limitations. First,
the possibility of selection bias in all studies considered
might have led to an over- or underestimation of the effect
of COPD on the index scores. Although the results are
based on data from a large COPD cohort that may be more
easily generalized than those of clinical studies, as well as on
a pooled control group from northern and southern
Germany, it cannot be excluded that they are not fully rep-
resentative for the entire German population. Second, the
necessity of standardized and comparable covariates
throughout all studies limited the range of variables that
could have been taken into account. In particular, a com-
parison of the influence of further comorbidities was limited
by the lack of comparable information. Therefore, the re-
ductions in HRQL in COPD grades might be explained
partly by the occurrence of other comorbidities that could
not be compared between COPD cases and control subjects.
This restriction could have led to an overestimation of the
effects of COPD on index scores. Third, the comorbidities
considered in our study may reflect historic conditions, such
as infarction or cancer. The effects of recent comorbid
events on HRQL might be more significant. Finally, the use
of pre-bronchodilator spirometry data to exclude subjects
with COPD from the control group might have led to a mis-
classification of subjects with asthma as COPD patients.
Therefore, subjects with FEV1/FVC ≥ 0.7 and self-reported
asthma were additionally excluded in order to create a lung-
healthy control group. This approach might have led to an
overestimation of the effects of COPD on HRQL scores be-
cause our control group might be healthier than a control
group excluding COPD patients only.
Conclusions
Compared with control subjects, generic HRQL is con-
siderably impaired in patients with COPD, even in early
Wacker et al. Respiratory Research  (2016) 17:81 Page 9 of 11
disease grades, and this was primarily caused by the lung
disease and not the comorbidities. As this impairment is
more pronounced in younger age groups, these patients are
a particularly relevant target group for specific or com-
prehensive disease management.
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